Literature DB >> 11959610

Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients.

Corrado Blandizzi1, Tecla Malizia, Giovanna Batoni, Emilia Ghelardi, Fabio Baschiera, Paolo Bruschini, Sonia Senesi, Mario Campa, Mario Del Tacca.   

Abstract

Azithromycin concentrations in the tonsils of 56 pediatric patients, treated with 10 or 20 mg of the drug per kg of body weight for 3 days, were compared. Azithromycin levels in plasma and tonsil samples were determined up to 8.5 days after the last dose. The 20-mg/kg regimen resulted in an improved tonsillar distribution of azithromycin, suggesting the achievement of enhanced therapeutic concentrations at infective sites of the upper respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959610      PMCID: PMC127138          DOI: 10.1128/AAC.46.5.1594-1596.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection.

Authors:  J Sastre Toraño; H J Guchelaar
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-12-11

2.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 4.  Microbiologic activity of the newer macrolide antibiotics.

Authors:  G H McCracken
Journal:  Pediatr Infect Dis J       Date:  1997-04       Impact factor: 2.129

5.  Selection of dose regimens of azithromycin .

Authors:  G Foulds; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

Review 6.  Advanced-generation macrolides: tissue-directed antibiotics.

Authors:  G W Amsden
Journal:  Int J Antimicrob Agents       Date:  2001       Impact factor: 5.283

7.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

8.  Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients.

Authors:  B P Vaudaux; J Cherpillod; P Dayer
Journal:  J Antimicrob Chemother       Date:  1996-06       Impact factor: 5.790

9.  Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children.

Authors:  L Pacifico; F Scopetti; A Ranucci; M Pataracchia; F Savignoni; C Chiesa
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 10.  Tissue-directed pharmacokinetics.

Authors:  J J Schentag; C H Ballow
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

View more
  1 in total

1.  Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment.

Authors:  Tina Kauss; Karen Gaudin; Alexandra Gaubert; Boubakar Ba; Serena Tagliaferri; Fawaz Fawaz; Jean-Louis Fabre; Jean-Michel Boiron; Xavier Lafarge; Nicholas J White; Piero L Olliaro; Pascal Millet
Journal:  Int J Pharm       Date:  2012-07-30       Impact factor: 5.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.